Description: NewAmsterdam is a clinical-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been sufficiently successful or well tolerated. NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, as the preferred LDL-C lowering therapy to be used as an adjunct to maximally tolerated statin therapy for high-risk cardiovascular disease (“CVD”) patients. Results from NewAmsterdam’s ROSE Phase 2b trial (presented at AHA Scientific Sessions in 2021) included observations that patients receiving obicetrapib 10 mg experienced a median reduction in LDL-C of 51% versus baseline in patients on high-intensity statin therapy (vs. a 7% reduction in the placebo arm). Based in the Netherlands, NewAmsterdam was founded in 2019 by the venture capital firm Forbion and John Kastelein, Chief Scientific Officer of the NewAmsterdam, and closed a $196 million (€160 million) Series A financing in January 2021 led by Forbion, Morningside Ventures and Ascendant BioCapital. In June 2022, NewAmsterdam entered into an exclusive licensing agreement with the Menarini Group for the commercialization of obicetrapib in Europe, while retaining all rights to commercialize obicetrapib, if approved, in the rest of the world, as well as rights to develop certain forms of obicetrapib for other diseases such as Alzheimer’s disease.
Home Page: www.newamsterdampharma.com
NAMS Technical Analysis
Gooimeer 2-35
Naarden,
1411 DC
Netherlands
Phone:
31 35 206 2971
Officers
| Name | Title |
|---|---|
| Dr. Michael Harvey Davidson FACC, Facp., M.D. | CEO, President, Executive Board Member & Director |
| Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D. | Founder, Chief Scientific Officer, Member of Executive Board & Director |
| Mr. Mayur Amrat Somaiya | Chief Financial Officer |
| Ms. Juliette Audet M.B.A., M.Sc. | Chief Business Officer |
| Mr. Douglas F. Kling | Chief Operating Officer |
| Ms. Louise Kooij | Chief Accounting Officer |
| Mr. Matthew Philippe | Executive VP &Head of Investor Relations |
| Mr. Bob Rambo | Executive Vice President of Marketing |
| Dr. Marc Ditmarsch M.D. | Chief Development Officer |
| Dr. Sheng Cui Ph.D. | Chief Manufacturing Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 6.1182 |
| Price-to-Sales TTM: | 70.3193 |
| IPO Date: | 2022-11-23 |
| Fiscal Year End: | December |
| Full Time Employees: | 62 |